learn from history, page-13

TDA - have enjoyed reading your posts over the last few years and hopefully you have enough in your SMSF to be interested to post more.

The last post from you was at 3.02 pm on the day of the announcement that you couldnt make it to the AGM due to family matters and you would be question the management on staffing issues etc and waiting to hear back from the management / other posters on the AGM. Just out of curiousity - did you sell before that post ? Or within the 1 hour after posting?

I also understand risk management and being wary of the unknown. Though I dont put ACL and TIS in the same basket (had gotten out of ACL around 55c albeit at a loss after the Long Term Risk/Reward got skewed). These are different companies, with different products, and different market sizes. Matter of fact I believe TIS did exactly what ACL did wrong - get a purely sales driven Partner with no other tangent interests.

My belief is that besides the Fund selling - a lot of investors got very nervous on the lack of detail - or so called lack of detail. Some even questioned whether the deal was actually done.

Regarding the fund selling - they have been doing it for the past 2 years capping the price and they only have a 2-3 day effect after which the SP moves back up.

Regarding the Lack of detail - I believe there is a LOT of detail in the presentation albeit the minute numbers are missing. One just has to read it well.

It does say that theere is an Agreement in Place with Quintiles (yet people asked if it has actually been signed).

It does say that the risk/reward will be shared and TIS will get higher revenue compared to a Pharma Licensing.

It does go on to say that VitroGro will be launched in 2011 Q2 in a market which is 44% of the World market size.

It does go on to present the capabilities of Quintiles which in Europe are much better than what S&N could have offered. A little further research on Quintiles would have easily demonstrated that fact.

I believe a lot of people just didnt read it too well or were fixated on S&N with an upfront payment (honestly ..i was one of them as well .. but i read the ppresentation in details before hitting on my sell button).

For me TIS presents a brilliant opportunity going by what Prof Harding had to say about the product and the fact that TIS will remain much more independent with Quintiles than with a Big Pharma.

My opinion ONLY - no advice given or intended - DYOR.